After Vivus (NASDAQ:VVUS) posted earnings last week, the company's share price took a big hit due to unimpressive sales of obesity drug Qsymia. With competitor Arena Pharmaceuticals (NASDAQ:ARNA) and its partner Eisai poised to enter this space with its own drug Belviq in the first quarter of next year, VIVUS might be starting to feel pressure to boost sales.

While investors need to continue watching Qsymia sales quarter to quarter, VIVUS looks determined to expand the possible uses for its flagship drug. In this video, Health Care Analyst Max Macaluso discusses a new clinical study that suggests Qsymia might widen its indication in the future.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.